WuXi Biologics Reports Strong 2022 Interim Results
- Written by PR Newswire
Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 MillionGross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 MillionNet Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 MillionTotal Backlog ReachedUS$18,467 Million
* ...
Read more: WuXi Biologics Reports Strong 2022 Interim Results














